BC Week In Review | Nov 9, 2018
Company News

Mirum launches with liver disease candidates from Shire

Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases. The start-up intends to...
BC Extra | Nov 7, 2018
Financial News

Mirum launches with liver disease candidates from Shire

Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases. The start-up intends to...
BC Week In Review | Aug 3, 2018
Company News

Shire earnings check Takeda's boxes

With its acquisition by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) due to close next half, Shire plc (LSE:SHP; NASDAQ:SHPG) reported 5% growth in 2Q18 revenue over 2Q17, outpacing the Japanese pharma's 0.4% growth over the same...
BC Extra | Jul 31, 2018
Company News

Shire earnings check Takeda's boxes

With its acquisition by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) due to close next half, Shire plc (LSE:SHP; NASDAQ:SHPG) reported 5% growth in 2Q18 revenue over 2Q17, outpacing the Japanese pharma's 0.4% growth over the same...
BC Extra | Apr 10, 2015
Top Story

Priority Review erases Shire's losses on trial miss

Shire plc (LSE:SHP; NASDAQ:SHPG) turned early losses on clinical data into gains on Thursday, picking up $7.24 to $254.32 on NASDAQ after FDA accepted for filing and granted Priority Review to an NDA for lifitegrast...
BC Week In Review | May 19, 2014
Company News

Lumena Pharmaceuticals, Shire deal

Shire will acquire Lumena for $260 million in cash up front. Lumena will also receive an undisclosed payment for its net cash and is eligible for undisclosed milestone payments tied to clinical trials of LUM001...
BioCentury | May 19, 2014
Finance

Luminous ROI

Luminous ROI Although Lumena Pharmaceuticals Inc. tested the IPO waters, its investors decided to take the bird in hand offered by Shire plc (LSE:SHP; NASDAQ:SHPG) and by doing so will get at least a 3.5x...
BC Extra | May 13, 2014
Company News

Shire to acquire Lumena

Shire plc (LSE:SHP; NASDAQ:SHPG) will acquire Lumena Pharmaceuticals Inc. (San Diego, Calif.) for $260 million in cash up front. Lumena will also receive an undisclosed payment for its net cash and is eligible for undisclosed...
BioCentury | Mar 17, 2014
Finance

Building a liver powerhouse

Building a liver powerhouse Lumena Pharmaceuticals Inc. will use last week's $45 million series B round to support expanded Phase II testing of LUM001 in cholestatic liver disease and a planned Phase II trial for...
BioCentury | May 13, 2013
Finance

Bile be gone

Bile be gone Lumena Pharmaceuticals Inc. is looking to advance its lead compound LUM001 through three Phase II cholestatic liver disease trials with funds from its $23 million series A. President and CEO Mike Grey...
Items per page:
1 - 10 of 10